ArticleDiabetology international2016

A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy.

Takeshi Yamamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.